PolyMedix, Inc.’s (PYMX) PMX-30063 Top-Class Defensin-Mimetic Antibiotic Displays Promising Activity Against Drug-Resistant Bacteria
PolyMedix, Inc., a biotechnology company focused on developing innovative therapeutic drugs to treat serious acute-care conditions, today announced that PMX-30063, its prime defensing-mimetic antibiotic, has displayed promising activity against 1,000 worldwide strains of Gram-positive staphylococci and streptococci clinical isolates, including strains resistant to linezolid, daptomycin, and methicillin. Evidence of these encouraging results was presented at the 21st Annual European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in London, United Kingdom. The presentation is available for viewing on PolyMedix’s website at www.Polymedix.com. "These important and encouraging data further substantiate the robust antimicrobial activity of PMX-30063 regardless of the existing mechanisms…